Hidden Fee Disclosure Act of 2025
HB2041, titled the Hidden Fee Disclosure Act of 2025, would amend ERISA’s employer-sponsored health plan disclosure rules to require more detailed reporting by covered service providers. The bill expands the categories of services that trigger disclosure obligations and clarifies that these requirements apply to a broader set of arrangements, including brokerage, consulting, plan design, claims repricing, benefits administration, stop-loss insurance, pharmacy benefit management, and third-party administration services.
A major focus of the bill is pharmacy benefit managers (PBMs) and third-party administrators for group health plans. It would require annual, written disclosures to plan fiduciaries about compensation, rebates, discounts, spread pricing, gross and net drug spending, pharmacy ownership, cost-sharing collected, and other fees or recoveries. It also defines PBM and third-party administration services more broadly and directs the Department of Labor to issue implementing regulations within one year.
The bill would affect ERISA-covered group health plans, plan fiduciaries, covered service providers, PBMs, insurers, administrators, and related subcontractors or affiliates. It also adds privacy-related guardrails by tying disclosures to HIPAA and HITECH privacy rules and limiting redisclosure, while preserving the Department of Labor’s access to the information. The amendments generally would apply only to contracts or arrangements entered into on or after January 1, 2026, including renewals and extensions.
The overall sentiment reflected in the available context is limited but appears generally supportive or reform-oriented, as the bill was introduced by bipartisan sponsors and framed as a transparency measure aimed at hidden fees. No committee debate or recorded votes are provided, so there is no documented opposition in the supplied materials. The bill’s structure suggests its proponents view it as a disclosure and accountability measure rather than a substantive prohibition on compensation practices.
The main points of contention likely center on the breadth and specificity of the required disclosures, the administrative burden on service providers and plan fiduciaries, and the handling of sensitive pricing and claims information. Potential concerns may also arise from the interaction between transparency requirements and privacy protections, as well as whether the bill’s detailed reporting mandates could expose proprietary contracting arrangements or increase compliance costs for employers and health plan vendors.
HB2041 would amend section 408(b)(2) of ERISA to broaden and clarify disclosure obligations for covered service providers to group health plans, especially PBMs and third-party administrators. It would require more granular reporting of compensation, rebates, discounts, spread pricing, recoveries, and plan drug spending, and it would expand the statutory definitions of covered services to capture more health-plan-related functions. The bill would also require the Department of Labor to issue implementing regulations and would apply prospectively to new, renewed, or extended arrangements beginning January 1, 2026.
Based on the bill text and the limited context provided, the measure appears to have a generally favorable, transparency-focused framing. It was introduced with bipartisan sponsorship and is presented as a consumer- and fiduciary-protection bill aimed at exposing hidden fees in employer-sponsored health plans. No votes or committee remarks are available, so there is no recorded opposition or support beyond the introduction itself.
The likely areas of contention are the scope and detail of the disclosure mandates, particularly for PBMs and third-party administrators that would need to report compensation streams, spread pricing, rebates, and ownership-related pharmacy spending. Critics may argue the bill imposes significant compliance and reporting burdens, could reveal sensitive commercial information, and may be difficult to implement consistently across complex health-plan arrangements. Supporters are likely to emphasize that the disclosures are necessary for fiduciaries to assess reasonableness, identify conflicts of interest, and understand drug and administrative costs.